This is a preview of subscription content, log in via an institution to check access.
Notes
Epigenomics and its collaboration with Roche was profiled in Pharmaceutical & Diagnostic Innovation 2004; 5 (2): 51–5.
The study was published in the Journal of Clinical Oncology 2006; 24 (2): 252–8.
Conformite Europeene.
References
Epigenomics. Epigenomics successfully completes biomarker validation study for prostate cancer classification test. Media release: 4 Jan 2006
European Biotechnology. Epigenomics AG: change of price target. New York: Lehman Brothers Global Equity Research, 2005
Epigenomics. Epigenomics DNA methylation test successfully detects colorectal cancer in blood. Media release: 19 Dec 2005
Iceland Genomics. EU consortium POLYGENE led by Iceland Genomics Corporation Receives a 3M € grant from the 6th Framework Programme to study inherited risk of breast and prostate cancer. Media release: 19 Dec 2005
Immunomedics. New diagnostic assay for pancreatic cancer reported in Journal of Clinical Oncology. Media release: 16 Dec 2005
MedMira. MedMira receives CE Mark for MiraCare Rapid HIV Test; Europeans now have access to first instant rapid HIV test. Media release: 17 Jan 2006
MedMira. MedMira granted hepatitis C patent in Europe; Patent further protects MedMira’s diagnostic technology. Media release: 3 Jan 2006
CeMines. CeMines® granted European Union regulatory clearance and CE Mark registration of its Cell Correct LAb® clinical Dx test for lung cancer. Media release: 11 Jan 2006
Tm Bioscience. Tm Bioscience cystic fibrosis test now has CE mark. Media release: 11 Jan 2006
Rights and permissions
About this article
Cite this article
Diagnostic Developments. Pharmaceutical & Diagnostic Innovation 4, 16–18 (2006). https://doi.org/10.1007/BF03257034
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03257034